447 research outputs found
A Review of Forest Resources and Forest Biodiversity Evaluation System in China
China is a country rich in diverse forest ecosystems due to the large span of the country, complex topography, and multiple climate regimes. In this paper, the basic information of forest resources in China was briefly introduced and the current state in the measurements of forest biodiversity and the establishment of forest biodiversity index systems in related studies were reviewed. The results showed that a lot of studies on forest biodiversity have been conducted mostly at landscape or stand level in China and the commonly used biodiversity indicators were identified and compared. Several comprehensive forest biodiversity index systems were proposed. However, there are still some problems during the construction of forest biodiversity assessment system. Due to the late establishment of biodiversity monitoring system in China, the availability of data that could be included in a forest biodiversity index system is limited, which hurdles the precise assessment of forest biodiversity. It is suggested to develop long-term monitoring stations and keep data recording consistently. Concerns should also be given to the construction of the framework of the forest biodiversity index system and the determination of the indicators’ weight. The results will provide reference for the establishment of national or regional forest biodiversity evaluation indicator systems in China
Recurrence-free Survival Prediction under the Guidance of Automatic Gross Tumor Volume Segmentation for Head and Neck Cancers
For Head and Neck Cancers (HNC) patient management, automatic gross tumor
volume (GTV) segmentation and accurate pre-treatment cancer recurrence
prediction are of great importance to assist physicians in designing
personalized management plans, which have the potential to improve the
treatment outcome and quality of life for HNC patients. In this paper, we
developed an automated primary tumor (GTVp) and lymph nodes (GTVn) segmentation
method based on combined pre-treatment positron emission tomography/computed
tomography (PET/CT) scans of HNC patients. We extracted radiomics features from
the segmented tumor volume and constructed a multi-modality tumor
recurrence-free survival (RFS) prediction model, which fused the prediction
results from separate CT radiomics, PET radiomics, and clinical models. We
performed 5-fold cross-validation to train and evaluate our methods on the
MICCAI 2022 HEad and neCK TumOR segmentation and outcome prediction challenge
(HECKTOR) dataset. The ensemble prediction results on the testing cohort
achieved Dice scores of 0.77 and 0.73 for GTVp and GTVn segmentation,
respectively, and a C-index value of 0.67 for RFS prediction. The code is
publicly available (https://github.com/wangkaiwan/HECKTOR-2022-AIRT). Our
team's name is AIRT.Comment: MICCAI 2022, HECKTOR Challenge Submissio
Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
<p>Abstract</p> <p>Background</p> <p>The concordance rate between IHC and FISH according to clinical performance is still controversial. We report a prospective study to reflect the concordance between IHC and FISH in Guilin city, People's Republic of China.</p> <p>Methods</p> <p>Fifty cases of invasive ductal carcinoma of breast tested by IHC and scored as 0, 1+, 2+ and 3+ by pathologists were further analyzed by FISH using a commercially available double-color probe, and the FISH findings were compared with IHC test results.</p> <p>Results</p> <p>A total concordance of 82.0% was observed with a Kappa coefficient of 0.640 (P < 0.001). A high discordance was observed in 30.0% of the patients with IHC 2+, 7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+.</p> <p>Conclusion</p> <p>The IHC can be used firstly to screen the HER-2 status, and FISH can be used as a supplementary role to IHC and 2+ and some negative cases. And only those cases with Her-2 status of IHC 3+ or FISH positive should be treated with Herceptin.</p
- …